National Institutes of Health (NIH) acting Director Ruth Kirschstein, M.D., announced today the appointment of Barnett Kramer, M.D., M.P.H., as the new Director of NIH's Office of Medical Applications of Research (OMAR), effective June 18, 2000.
"Dr. Kramer has a distinguished record of leadership at the NIH and we are delighted that he is taking the helm at OMAR," says Dr. Kirschstein. "He's a seasoned clinician, scientist, and administrator who will bring strong managerial skills and innovative thinking to OMAR and the NIH Consensus Program."
"This is a very exciting opportunity," says Dr. Kramer, "The application of research findings is a core mission of NIH. OMAR and the Consensus Program have played an important role in fulfilling this mission and I'm eager to continue and expand that tradition."
A component of the NIH Office of Disease Prevention, OMAR is the focal point for NIH efforts to translate the results of biomedical research into knowledge that can be used effectively in the delivery of health services. A major responsibility of OMAR is the coordination and management of the NIH Consensus Development Program. Under this program, OMAR organizes major conferences on controversial public health issues.
Dr. Kramer comes to OMAR from the National Cancer Institute (NCI), where since 1996 he has served as Deputy Director of NCI's Division of Cancer Prevention. He also is currently the editor-in-chief of the Journal of the National Cancer Institute, and a clinical professor in the department of medicine of the Uniformed Services University of the Health Sciences in Bethesda, Maryland.
A 1973 graduate of the University of Maryland Medical School, Dr. Kramer completed his internship and residency training in internal medicine at Barnes Hospital in St. Louis, Missouri. Dr. Kramer is board certified in internal medicine and medical oncology and in 1991 received a master's degree in public health from the Johns Hopkins University School of Hygiene and Public Health.
Dr. Kramer has extensive experience in cancer treatment studies, primary prevention studies, as well as clinical screening trials of lung, ovarian, breast, and prostate cancers.
"Dr. Kramer's background and experience make him ideally suited for advancing the objectives of OMAR and the Consensus Program," says William R. Harlan, M.D., Director of the NIH Office of Disease Prevention.
Two NIH Consensus Development Conferences are scheduled for the fall of 2000: Screening and Management of Phenylketonuria (PKU) takes place October 16-18, 2000; and Adjuvant Therapy for Breast Cancer will be held from November 1-3, 2000. Please see the Consensus Program Web site -- http://consensus.nih.gov/ -- for more information.
The Office of the Director is a component of the National Institutes of Health, U.S. Department of Health and Human Services.